Last Update 09 Apr 26

Fair value Increased 0.26%

JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience

Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks.

Analyst Commentary

Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely. While most of the commentary leans constructive, there are still some balanced views around execution risk and pipeline delivery.

Bullish Takeaways

Bullish analysts are lifting price targets into the US$250 to US$280 range, linking their moves to confidence in the product pipeline, especially newer therapies such as Tremfya, Tecvayli and Inlexzo, which they see as meaningful for long term growth in key disease areas.
Several research notes tie higher valuation to medical technology trends, with Johnson & Johnson included in groups where fundamentals are described as "healthy" even during recent sector volatility. This supports the case for resilient execution across core franchises.
Some bullish analysts highlight that stronger data for specific oncology assets could indirectly support other established products like Darzalex through longer treatment duration. They see this as supportive to future revenue mix and margin quality.
Large firms such as JPMorgan and Citi reference updated models and group level target resets that include Johnson & Johnson among preferred names in medical technology. This reinforces the idea that the stock screens well on growth prospects versus peers in their coverage.

Bearish Takeaways

Even as price targets move higher, some analysts maintain Neutral stances. This signals that they see the valuation as closer to fair value after the recent rerating, with less obvious upside without flawless execution on the late stage pipeline.
Commentary that raises targets while still flagging an "uncertain macro backdrop" and rising geopolitical risk suggests concern that healthcare flows into the sector could be sensitive to shifts in risk appetite. This might cap near term multiple expansion.
A portion of the research commentary points out that sector level clarity on policy and reimbursement is still evolving. While healthcare stocks have recently performed better, cautious analysts are not treating that as a firm foundation for sustained revaluation.
Some Neutral ratings, even with higher price targets, imply that any misstep in ramping products like Tremfya or in converting pipeline assets such as Tecvayli and Inlexzo into consistent revenue could challenge the current fair value assumptions embedded in these models.

What’s in the News

Reports indicate Johnson & Johnson is preparing a potential sale of its DePuy Synthes orthopedics unit. Media cite an estimated value of more than US$20b and interest from multiple private equity firms and possible strategic buyers (Bloomberg, M&A rumors).
A California judge vacated a US$950m punitive damages award in a talc case, ruling that plaintiffs did not sufficiently prove Johnson & Johnson acted with malice or concealed required safety information (Reuters).
Separately, a Pennsylvania jury awarded US$250,000 in a baby powder ovarian cancer case, adding to ongoing talc litigation that includes tens of thousands of related lawsuits in U.S. courts (Philadelphia Court of Common Pleas reporting).
A nationwide Canadian class action related to talc based baby powder has been certified, alleging inadequate warnings about a potential ovarian cancer risk and seeking damages under product liability and consumer protection statutes, while Johnson & Johnson denies the allegations (Ontario Superior Court of Justice filing).
Broader policy headlines include a U.S. district court ruling that recent federal limits on vaccines were not based on science. Johnson & Johnson is listed alongside other vaccine and large cap drug manufacturers as potentially affected by changes in access barriers (NYT).

Valuation Changes

Fair Value: The updated fair value estimate has risen slightly from $241.08 to $241.71 per share, reflecting a modest adjustment to the model assumptions.
Discount Rate: The discount rate is essentially unchanged at 6.98%, indicating a consistent view of Johnson & Johnson's risk profile.
Revenue Growth: The assumed long term revenue growth rate has edged higher from 6.16% to 6.24%, a small uplift in expectations for top line expansion in dollar terms.
Net Profit Margin: The forecast net profit margin has shifted marginally from 22.51% to 22.45%, pointing to a slightly more conservative view on future profitability.
Future P/E: The assumed future P/E multiple has moved from 28.17x to 28.25x, indicating only a very small change in the valuation multiple applied to projected earnings.

10 views

Key Takeaways

Johnson & Johnson is poised for growth in immunology and oncology despite facing challenges from loss of drug exclusivity, leveraging next-gen therapies for strengthened revenue.
Strategic investments in U.S. operations, acquisitions, and MedTech expansion aim to boost future earnings and efficiency, with potential restructuring in surgery to aid profitability.
Loss of exclusivity for key products and tariffs could significantly threaten revenue and margins, while ongoing litigation poses financial risks.

Catalysts

About Johnson & Johnson

Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.What are the underlying business or industry changes driving this perspective?

Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity. This is expected to bolster revenues through next-generation therapies and significant market share gains in oncology and immunology.
The company's substantial investment of over $55 billion into manufacturing, R&D, and technology in the U.S. over the next four years is projected to expand capacity for advanced medicines and devices, potentially increasing operational efficiency and future earnings.
Recent acquisitions, such as Intra-Cellular Therapies, are expected to contribute substantial revenue streams, with products like CAPLYTA potentially reaching over $5 billion in peak sales, positively affecting the company’s revenue and EPS in the future.
Ongoing expansion within MedTech, highlighted by strong performance from acquired cardiovascular units Abiomed and Shockwave, as well as developments in robotic surgery, are expected to drive revenue growth and enhance adjusted income margins over time.
The company plans significant restructuring in their surgery business within MedTech to streamline operations and improve efficiency, anticipated to have short-term revenue disruptions but expected to enhance long-term profitability and margin expansion.

Johnson & Johnson Earnings and Revenue Growth

Johnson & Johnson Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Johnson & Johnson's revenue will grow by 6.2% annually over the next 3 years.
Analysts assume that profit margins will shrink from 28.5% today to 22.5% in 3 years time.
Analysts expect earnings to reach $25.4 billion (and earnings per share of $10.88) by about April 2029, down from $26.8 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $21.9 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 28.3x on those 2029 earnings, up from 21.7x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 16.5x.
Analysts expect the number of shares outstanding to grow by 0.16% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Loss of exclusivity for STELARA and the impact of biosimilar competition could significantly erode revenue from one of Johnson & Johnson's major products. This could affect overall revenue and net margins, especially in the innovative medicine segment.
Tariffs, particularly those related to exports to China, could increase costs and impact the net margins negatively, due to increased cost of goods sold from tariffs being relieved through the P&L in future periods.
The ongoing litigation related to talc, though controlled for now, poses a continual risk to financial stability and could impact net earnings and cash flow, particularly if adverse judgments or settlements occur.
The orthopedics segment faced headwinds, including competitive pressures and challenges in the spine and sports areas. Ongoing issues could impact revenue and earnings unless the planned innovations drive a turnaround.
Potential dilution from acquisitions such as Intra-Cellular Therapies and the impact of tariffs could affect operating margin improvement efforts, challenging overall earnings and net margins despite robust sales growth in some areas.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $241.71 for Johnson & Johnson based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $285.0, and the most bearish reporting a price target of just $155.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $113.0 billion, earnings will come to $25.4 billion, and it would be trading on a PE ratio of 28.3x, assuming you use a discount rate of 7.0%.
Given the current share price of $241.3, the analyst price target of $241.71 is 0.2% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Johnson & Johnson?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments